🇺🇸 US

TXG revenue, net income and debt history (10x Genomics, Inc.)

Quick answer

10x Genomics, Inc. (TXG) reported revenue of $642.8M and net loss of $43.5M for the fiscal year ended 2025-12-31, up 5.2% from $610.8M the year before, per its 10-K filed with the SEC on 2026-02-13.

✓ SEC EDGAR XBRL company facts (10-K/10-Q filings)

Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)

Fiscal yearRevenueNet incomeLong-term debt
2025 (FY ending 2025-12-31)$642.8M-$43.5M—
2024 (FY ending 2024-12-31)$610.8M-$182.6M—
2023 (FY ending 2023-12-31)$618.7M-$255.1M—
2022 (FY ending 2022-12-31)$516.4M-$166.0M—
2021 (FY ending 2021-12-31)$490.5M-$58.2M—
2020 (FY ending 2020-12-31)$298.8M-$542.7M$0.0M
2019 (FY ending 2019-12-31)$245.9M-$31.3M$29.7M
2018 (FY ending 2018-12-31)$146.3M-$112.5M$25.5M
2017 (FY ending 2017-12-31)$71.1M-$18.8M—

Related

Last updated 2026-10-16. Data only, not financial or tax advice.